File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Identification of an upper limit of tumor burden for downstaging in candidates with hepatocellular cancer waiting for liver transplantation: a West-East collaborative effort

TitleIdentification of an upper limit of tumor burden for downstaging in candidates with hepatocellular cancer waiting for liver transplantation: a West-East collaborative effort
Authors
Keywordsdisease progression
loco-regional therapy
alpha-fetoprotein
mRECIST
MELD
Issue Date2020
PublisherMDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/cancers/
Citation
Cancers, 2020, v. 12 n. 2, p. article no. 452 How to Cite?
AbstractSince the introduction of Milan Criteria, all scoring models describing the prognosis of hepatocellular cancer (HCC) after liver transplantation (LT) have been exclusively based on characteristics available at surgery, therefore neglecting the intention-to-treat principles. This study aimed at developing an intention-to-treat model through a competing-risk analysis. Using data available at first referral, an upper limit of tumor burden for downstaging was identified beyond which successful LT becomes an unrealistic goal. Twelve centers in Europe, United States, and Asia (Brussels, Sapienza Rome, Padua, Columbia University New York, Innsbruck, Medanta-The Medicity Dehli, Hong Kong, Kyoto, Kaohsiung Taiwan, Mainz, Fukuoka, Shulan Hospital Hangzhou) created a Derivation (n = 2318) and a Validation Set (n = 773) of HCC patients listed for LT between January 2000–March 2017. In the Derivation Set, the competing-risk analysis identified two independent covariables predicting post-transplant HCC-related death: combined HCC number and diameter (SHR = 1.15; p < 0.001) and alpha-fetoprotein (AFP) (SHR = 1.80; p < 0.001). WE-DS Model showed good diagnostic performances at internal and external validation. The identified upper limit of tumor burden for downstaging was AFP ≤ 20 ng/mL and up-to-twelve as sum of HCC number and diameter; AFP = 21–200 and up-to-ten; AFP = 201–500 and up-to-seven; AFP = 501–1000 and up-to-five. The WE-DS Model proposed here, based on morphologic and biologic data obtained at first referral in a large international cohort of HCC patients listed for LT, allowed identifying an upper limit of tumor burden for downstaging beyond which successful LT, following downstaging, results in a futile transplantation.
Persistent Identifierhttp://hdl.handle.net/10722/286359
ISSN
2018 Impact Factor: 6.162
2015 SCImago Journal Rankings: 1.630

 

DC FieldValueLanguage
dc.contributor.authorLai, Q-
dc.contributor.authorVitale, A-
dc.contributor.authorHalazun, K-
dc.contributor.authorIesari, S-
dc.contributor.authorViveiros, A-
dc.contributor.authorBhangui, P-
dc.contributor.authorMennini, G-
dc.contributor.authorWong, T-
dc.contributor.authorUemoto, S-
dc.contributor.authorLin, CC-
dc.contributor.authorMittler, J-
dc.contributor.authorIkegami, T-
dc.contributor.authorZhe, Y-
dc.contributor.authorZheng, SS-
dc.contributor.authorSoejima, Y-
dc.contributor.authorHoppe-Lotichius, M-
dc.contributor.authorChen, CL-
dc.contributor.authorKaido, T-
dc.contributor.authorLo, CM-
dc.contributor.authorRossi, M-
dc.contributor.authorSoin, AS-
dc.contributor.authorFinkenstedt, A-
dc.contributor.authorEmond, JC-
dc.contributor.authorCillo, U-
dc.contributor.authorLerut, J-
dc.date.accessioned2020-08-31T07:02:45Z-
dc.date.available2020-08-31T07:02:45Z-
dc.date.issued2020-
dc.identifier.citationCancers, 2020, v. 12 n. 2, p. article no. 452-
dc.identifier.issn2072-6694-
dc.identifier.urihttp://hdl.handle.net/10722/286359-
dc.description.abstractSince the introduction of Milan Criteria, all scoring models describing the prognosis of hepatocellular cancer (HCC) after liver transplantation (LT) have been exclusively based on characteristics available at surgery, therefore neglecting the intention-to-treat principles. This study aimed at developing an intention-to-treat model through a competing-risk analysis. Using data available at first referral, an upper limit of tumor burden for downstaging was identified beyond which successful LT becomes an unrealistic goal. Twelve centers in Europe, United States, and Asia (Brussels, Sapienza Rome, Padua, Columbia University New York, Innsbruck, Medanta-The Medicity Dehli, Hong Kong, Kyoto, Kaohsiung Taiwan, Mainz, Fukuoka, Shulan Hospital Hangzhou) created a Derivation (n = 2318) and a Validation Set (n = 773) of HCC patients listed for LT between January 2000–March 2017. In the Derivation Set, the competing-risk analysis identified two independent covariables predicting post-transplant HCC-related death: combined HCC number and diameter (SHR = 1.15; p < 0.001) and alpha-fetoprotein (AFP) (SHR = 1.80; p < 0.001). WE-DS Model showed good diagnostic performances at internal and external validation. The identified upper limit of tumor burden for downstaging was AFP ≤ 20 ng/mL and up-to-twelve as sum of HCC number and diameter; AFP = 21–200 and up-to-ten; AFP = 201–500 and up-to-seven; AFP = 501–1000 and up-to-five. The WE-DS Model proposed here, based on morphologic and biologic data obtained at first referral in a large international cohort of HCC patients listed for LT, allowed identifying an upper limit of tumor burden for downstaging beyond which successful LT, following downstaging, results in a futile transplantation.-
dc.languageeng-
dc.publisherMDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/cancers/-
dc.relation.ispartofCancers-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectdisease progression-
dc.subjectloco-regional therapy-
dc.subjectalpha-fetoprotein-
dc.subjectmRECIST-
dc.subjectMELD-
dc.titleIdentification of an upper limit of tumor burden for downstaging in candidates with hepatocellular cancer waiting for liver transplantation: a West-East collaborative effort-
dc.typeArticle-
dc.identifier.emailWong, T: wongtcl@hku.hk-
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hk-
dc.identifier.authorityWong, T=rp01679-
dc.identifier.authorityLo, CM=rp00412-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/cancers12020452-
dc.identifier.scopuseid_2-s2.0-85079608583-
dc.identifier.hkuros313696-
dc.identifier.volume12-
dc.identifier.issue2-
dc.identifier.spagearticle no. 452-
dc.identifier.epagearticle no. 452-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats